Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG68CL
|
|||
| Drug Name |
TTP399
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [1] | |
| Type-1 diabetes [ICD-11: 5A10] | Phase 1/2 | [2] | ||
| Company |
vTv Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02405260) Add Glucokinase Activator to Target A1c (AGATA). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03335371) Evaluation of TTP399 in Patients With Type 1 Diabetes (SimpliciT1). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of vTv Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.